Gene Therapy Platform Articles & Analysis
24 news found
Caroline Man Xu, Co-founder and CEO of ViGeneron said:” Recombinant AAV vectors are an established platform for effective gene therapies today. However, their limited packaging capacity and transduction efficacy are a major challenge for the development of novel gene therapies. ...
The proceeds will enable ViGeneron to accelerate its proprietary viral vector-based gene therapy platforms and drive product development in its two lead ophthalmic gene therapy programs. ...
“In addition, positive study outcomes from our cell & gene therapy platforms offer a potential upside that is hard to quantify exactly today but can reach multi-billion Euro ...
ByBayer AG
Under this agreement, the companies will work together to potentially discover precision genetic medicines through the development of a novel platform for full gene insertion by single vector delivery of gene editing and DNA cargoes. ...
ByBayer AG
Agreement strengthens Bayer’s new cell and gene therapy platform further Supports Mammoth’s vision of unlocking the full potential of novel CRISPR systems Mammoth to receive upfront payment of USD 40 million, and potential future milestone payments of more than one billion USD upon successful achievement Bayer AG and Mammoth ...
“We continue our ambitious mission to enable access to life changing gene therapies by fulfilling a key goal of bringing them from concept to reality,” said Timothy J. ...
(“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies using its proprietary gene circuit platform, today announced the completion of its business combination with Dynamics Special Purpose Corp. ...
(Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today reported financial results for the first quarter ended March 31, 2022 and provided a business update. ...
Regeneron receives access to ViGeneron’s vgAAV capsids for one inherited retinal disease target and an option for an exclusive license to develop and commercialize the gene therapy product ViGeneron is eligible to receive upfront payment, research funding, option exercise fee, development and commercial milestone payments, plus royalties on net sales ...
Aurealis Therapeutics, a synthetic biology company developing groundbreaking four-in-one cell and gene therapies and Xbiome, an AI-based microbiome drug development company, today announced that the two companies have entered into an exclusive license and collaboration agreement for the clinical development and commercialization of Aurealis investigational ...
Ella Korets-Smith, Chief Business Officer of Virica Biotech, said: “There is growing demand from major industry players to use leading lentivirus technologies, like Oxford Biomedica’s LentiVector® platform, to develop cell and gene therapies. We envision our VSEs™ as an ideal solution in their quest to pursue new ways to ...
COVAXIN™ (BBV152) is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform. With more than 180 million doses having been administered to adults outside the U.S., COVAXIN™ (BBV152) is currently authorized under emergency use in 17 countries, and applications for emergency use authorization are pending in more than 60 ...
“The results suggest that COVAXIN™, which is made on the same platform used in traditional polio pediatric vaccines for decades, when administered in a two-dose series to children between 2-18, may offer an option that is safe while delivering a robust immune ...
COVAXIN™ is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform. With more than 125 million doses having been administered to adults outside the U.S., COVAXIN™ is currently authorized under emergency use in 17 countries, and applications for emergency use authorization are pending in more than 60 other countries. ...
Epidermolysis bullosa (EB), better known as butterfly baby disease, is a genetic disorder that involves the continuous formation of bullous lesions on the skin, due to very small mechanical trauma and minimal rubbing, which strongly impact the quality of life of these patients. Depending on the type of mutated gene, it is distinguished in different forms, of which the most severe are Junctional ...
With this final decision by the FDA, we are embarking on a new pathway of care through this innovative gene therapy.” Ocugen’s modifier gene therapy platform aims to target nuclear hormone receptors (NHRs) that regulate multiple functions within the retina, giving it the potential to address many ...
COVAXIN™ is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform. With more than 100 million doses having been administered to adults outside the U.S., COVAXIN™ is currently authorized under emergency use in 17 countries, and applications for emergency use authorization are pending in more than 60 other countries. ...
About PsiOxus PsiOxus is a clinical stage oncology company pioneering systemic immune oncology products that drive sustained reprogramming of the tumor microenvironment to overcome the central challenge of resistance to therapy. Our flexible and validated T-SIGn® vector platform can deliver multiple transgene payloads that re-engineer both primary and ...
About T-SIGn® Tumor-Specific Immuno-Gene Therapy (T-SIGn) is a broad platform for tumor re- engineering by delivering combinations of transgenes encoding immunotherapeutic proteins. ...
NG-641, is a tumor re-engineering product using PsiOxus’ proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn) platform based upon the enadenotucirev vector. ...